3 min read

Risk-based thinking (ICH Q9) for pharmacists

This article explains the framework and applies it to a familiar setting: the pharmacy dispensing process.
Risk-based thinking (ICH Q9) for pharmacists

Pharmacists make risk decisions all day. Should this interaction be flagged to the prescriber? Can this medicine still be used after a short temperature excursion? Is this new symptom worth a report? Most of these decisions are made intuitively, based on experience.

ICH Q9, the international guideline on quality risk management, turns that intuition into a structured, documented process (International Council for Harmonisation [ICH], 2023). This article explains the framework and applies it to a familiar setting: the pharmacy dispensing process.

The two principles of ICH Q9

ICH Q9 rests on two principles:

  1. The evaluation of risk to quality should be based on scientific knowledge and ultimately linked to the protection of the patient (ICH, 2023).
  2. The level of effort, formality and documentation should be proportionate to the level of risk (ICH, 2023).

The second principle is often forgotten. Not every decision needs a formal risk assessment. A high-risk change to a sterile manufacturing process does; a minor wording update to a work instruction usually does not.

The revised guideline, ICH Q9(R1), adopted in 2023, added clarification on subjectivity in risk assessments, the appropriate level of formality, risk-based decision-making and risks to product availability (ICH, 2023).

The risk management process

ICH Q9 describes a cycle with clear steps:

  • Risk assessment: identify hazards, analyse the risk of each one and evaluate it against criteria.
  • Risk control: reduce risks to an acceptable level, then decide whether any remaining risk can be accepted.
  • Risk communication: share the outcome with the people who need it.
  • Risk review: revisit the assessment when new knowledge or events arise.

Risk is usually described as a combination of the probability of harm and its severity. Many tools also consider detectability: how likely the problem is to be caught before it reaches the patient (ICH, 2023).

Common tools

The guideline describes several tools. Choosing the right one is part of proportionality.

ToolBest suited for
Fishbone (Ishikawa) diagramBrainstorming possible causes of a problem
Risk ranking and filteringComparing and prioritising many risks quickly
Preliminary hazard analysisEarly assessment when little detail is known
FMEA (failure mode and effects analysis)Systematically analysing each step of a process
HACCPIdentifying critical control points in a process

Worked example: FMEA of a dispensing process

FMEA scores each potential failure for severity (S), occurrence (O) and detectability (D), here on a scale of 1 to 5. Multiplying them gives a risk priority number (RPN; Stamatis, 2003). The scores below are illustrative.

Process stepFailure modeSODRPNControl measure
Selecting the productWrong strength from look-alike packaging53345Barcode scanning; separate storage of look-alike strengths
Checking the prescriptionClinically relevant interaction missed52330Interaction software plus pharmacist review of high-risk combinations
LabellingWrong dosage instructions42216Final pharmacist check before handover
StorageRefrigerator failure overnight4128Continuous monitoring with alarm

The highest RPN points to where controls are most needed. After new controls are introduced, the failure modes are scored again to confirm that the risk has fallen.

The value of this exercise is not the numbers themselves. It is the structured conversation it forces: what can go wrong, how bad it would be, and whether we would notice in time.

Avoiding common pitfalls

Risk assessments can create false confidence if they are done badly. Common pitfalls include:

  • Subjectivity: scores depend on who is in the room. A diverse team and clear scoring definitions reduce bias (ICH, 2023).
  • Box-ticking: assessments written to justify a decision already made.
  • Never reviewing: an assessment that is not updated after incidents or changes quickly becomes outdated.

Quality risk management and drug safety risk management

Pharmacists moving into industry will meet two related uses of the word "risk management". ICH Q9 deals with risks to product quality. Pharmacovigilance risk management, described in ICH E2E and set out in risk management plans (European Medicines Agency [EMA], 2017; ICH, 2004), deals with the safety risks of a medicine in patients.

The logic is similar: identify risks, characterise them, minimise them and check whether the measures work. Understanding both helps in roles where quality and safety meet, such as product complaints that might also be adverse events.

Why this matters to employers

Risk-based thinking is expected in every regulated function, from quality assurance to regulatory affairs and pharmacovigilance. My practice as a pharmacist, in hospitals and community settings, gave me years of real-world risk decisions. My MSc training in early safety assessment, chemical risk assessment and regulatory science gave me the formal frameworks to structure and document them.

Key takeaways

  • ICH Q9 links risk to patient protection and requires effort proportionate to risk.
  • Tools such as FMEA turn intuitive judgement into documented decisions.
  • Quality risk management and pharmacovigilance risk management follow a shared logic.

References

European Medicines Agency. (2017). Guideline on good pharmacovigilance practices (GVP): Module V – Risk management systems (Rev 2). https://www.ema.europa.eu

International Council for Harmonisation. (2004). Pharmacovigilance planning E2E. https://www.ich.org

International Council for Harmonisation. (2023). Quality risk management Q9(R1). https://www.ich.org

Stamatis, D. H. (2003). Failure mode and effect analysis: FMEA from theory to execution (2nd ed.). ASQ Quality Press.